Liposomes modified with cyclic RGD peptide for tumor targeting

Journal of Drug Targeting

Volumn 12, Issue 5, 2004, Pages 257-264

  Dubey, Praveen K ^a   Mishra, Vivek ^a   Jain, Sanyog ^a   Mahor, Sunil ^a   Vyas, S P ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Angiogenesis; Cyclic RGD peptide; Metastasis; Sterically stabilized liposomes; Tumor targeting

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; CHOLESTEROL; DISTEAROYLPHOSPHATIDYLCHOLINE; DRUG CARRIER; FLUOROURACIL; LIPOSOME; MACROGOL; PHOSPHATIDYLETHANOLAMINE; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING KINETICS; BIOASSAY; CANCER REGRESSION; CHEMICAL MODIFICATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG LIVER LEVEL; DRUG SELECTIVITY; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; ENCAPSULATION; ENDOTHELIUM CELL; GENE OVEREXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID COMPOSITION; LUNG METASTASIS; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; UMBILICAL VEIN;

ANIMALS; CELLS, CULTURED; FLUOROURACIL; HUMANS; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES, CYCLIC;

EID: 4644349816     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/10611860410001728040     Document Type: Article

References (27)

1. Arap, W., Pasqualini, R. and Ruoslahti, E. (1998) "Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model", Science 279, 377-380.
2. Bartlett, G.R. (1959) "Phosphorus assay in column chromatography", J. Biol. Chem. 234, 466-468.
3. Boehm, T., Folkman, J., Browder, T. and O'Reilly, M.S. (1997) "Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance", Nature 390, 404-407.
4. 3 for angiogenesis", Science 264, 569-571.
5. Compagnon, P., Thiberville, L., Moore, N., Thuillez, C. and Lacroix, C. (1996) "Simple high-performance liquid chromatographic method for the quantitation of 5-fluorouracil in human plasma", J. Chromatogr. B 677, 380-383.
6. Ellerby, H.M., Arap, W., Ellerby, L.M., Kain, R., Andrusiak, R., Rio, G.D., Krajewaski, S., Lombardo, C.R., Rao, R., Ruoslahti, E., Bredesen, D.E. and Pasqualini, R. (1999) "Anticancer activity of targeted pro-apoptotic peptides", Natl Med. 5, 1032-1038.
7. Fidler, I. (1973) "Selection of successive tumor lines for metastasis", Natl New Biol. 242, 148-149.
8. Fidler, I.J. (1984) "The Ernst W. Bertner memorial award lecture: the evolution of biological heterogeneity in metastatic neoplasms", In: Nicolson, G.I. and Milas, I., eds, Cancer Invasion and Metastasis. Biologic and Therapeutic Aspects (Rason Press, New York , pp 5-9.
9. Fields, G.B. and Noble, R.L. (1990) "Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl arnino acids", Int. J. Pept. Protein Res. 35, 161-214.
10. Forssen, E. and Willis, W. (1998) "Ligand targeted liposomes", Adv. Drug Deliv. Rev. 29, 249-271.
11. v integrins", Science 270, 1500-1502.
12. 3 integrin", J. Clin. Invest. 88, 1924-1932.
13. Hynes, R.O. (2002) "A reevaluation of integrins as regulators of angiogenesis", Natl Med. 8(9), 918-921.
14. Jaffe, E.A., Nachman, R.L., Becker, C.G. and Minick, C.R. (1973) "Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria", J. Clin. Invest. 52, 2745-2756.
15. Koivunen, E., Wang, B. and Ruoslahti, E. (1995) "Phage libraries displaying cyclic peptides with different ring sizes: Ligand specificities of the RGD-directed integrins", Biotechnology 13, 265-270.
16. 3 Integrin Directed Therapeutics", Bioconjug. Chem. 13, 128-135.
17. Kreisle, R.A. and Ershler, W.B. (1988) "Investigation of tumor angiogenesis in an id mouse model: role of host tumor interaction", J. Natl Cancer Inst. 80, 845-849.
18. Kumar, C.C., Armstrong, L., Yin, Z., Malkowski, M., Maxwell, E., Ling, H., Yaremko, B., Liu, M., Verner, J., Smith, E.M., Neustadt, B. and Nechuta, T. (2000) "Targeting integrins alpha v beta3 and alpha v beta 5 for blocking tumor-induced angiogenesis", Adv. Exp. Med. Biol. 476, 169-180.
19. Marsh, D.A. (1990) CRC Handbook of Lipid Bilayers (CRC Press, Boca Raton), pp 163-168.
20. Martin, F.J. (1998) "Clinical pharmacology and antitumor efficacy of DOXIL (pegylated liposomal doxorubicin)", In: Lasic, D.D. and Papahadjopoulos, D., eds, Medical Applications of Liposomes (Elsevier Science BV, New York), pp 635-688.
21. McCusker, F.C., Kocienski, P.J., Boyle, T. and Schatzlein, A.G. (2002) "Solid-phase synthesis of c(RGDfK) derivatives: On-resin cyclisation and lysine functionalisation", Bioorg. Med. Chem. Lett. 12, 547-549.
22. New, R.R.C. (1990) In: New, R.R.C., ed., Liposomes: A Practical Approach (Oxford University Press, Oxford), pp 33-104.
23. Papahadjopoulos, D. and Gabizon, A.A. (1995) "Sterically stabilized (stealth) liposomes: pharmacological properties and drug carrying potential in cancer", In: Philippot, J.R. and Schuber, F., eds, Liposomes as Tools in Basic Research and Industry (CRC Press, Boca Raton, FL), pp 177-188.
24. Schiffelers, R.M., Koning, G.A., ten Hagen, T.L.M., Fens, M.H.A.M., Schraa, A.J., Janssen, A.P.C.A., Kok, R.J., Molema, G. and Storm, G. (2003) "Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin", J. Control. Rel. 91, 115-122.
25. 3 in pig, dog and cattle", Histol. Histopathol. 16, 1037-1046.
26. Streit, M., Riccardi, L., Velasco, P., Brown, L.F., Hawighorst, T., Bornstein, P. and Detmar, M. (1999) " Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis", Proc. Natl Acad. Sci. USA 96, 14888-14893.
27. Szoka, F., Jr. and Papahadjopoulos, D. (1978) "Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation", Proc. Natl Acad. Sci. USA 75, 4194-4198.